The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine

Psychopharmacology

Volumn 119, Issue 4, 1995, Pages 428-439

  Cools, A R ^a   Prinssen, E P M ^a   Ellenbroek, B A ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Atypical neuroleptics; Locomotor activity; N. accumbens; Olfactory tubercle; Paw test

Indexed keywords

2,3,3A,12B TETRAHYDRO 3 METHYL 1H DIBENZO[B,F]OXEPINO[10,11 C]PYRROLE; DOPAMINE; ERGOMETRINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PROTHIPENDYL; RISPERIDONE; SERTINDOLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; FORELIMB; HINDLIMB; HISTOLOGY; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY NUCLEUS; PRIORITY JOURNAL; PSYCHOSIS; RAT;

ANIMAL; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; DIBENZOXEPINS; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; INDOLES; LOCOMOTION; MALE; OLFACTORY PATHWAYS; PIRENZEPINE; RATS; RATS, WISTAR; RISPERIDONE; SUPPORT, NON-U.S. GOV'T; THIAZINES; TIME FACTORS;

EID: 0029020015     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/BF02245859     Document Type: Article

References (65)

1. Neurobehavioral screening in rats: validation study
2. Pharmacological profile of ritanserin: a very specific central serotonin S2 antagonist
3. Effects of haloperidol and low doses of clozapine on the acetylcholine turnover in rat forebrain structures
4. Clinical overview of risperidone
5. Risperidone: clinical safety and efficacy in schizophrenia
6. One year follow-up study with risperidone in chronic schizophrenia
7. Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors
8. Norepinephrine and dopamine in the limbic system of the rat
9. Dopamine-containing neurons in the mammalian central nervous system: electrophysiology and pharmacology
10. Clinical review of risperidone
11. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
12. Anatomical analysis of the involvement of mesolimbocortical dopamine in the locomotor stimulant actions of d-amphetamine and apomorphine
13. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicenter double-blind comparative study
14. Mesolimbic dopamine and its control of locomotor activity in rats: differences in pharmacology and light/dark periodicity between the olfactory tubercle and the nucleus accumbens
15. Similarities and dissimilarities between the pharmacology of dopamine-dependent behaviour elicited from distinct mesolimbic structures
16. Excitation-mediating and inhibition-mediating dopamine receptors: a new concept towards a better understanding of electrophysiological, biochemical, functional and clinical data
17. Interaction between aminergic systems in mesolimbic structures: the importance of 5-HT2, D2 and D1 receptors in the olfactory tubercle for the atypical profile of neuroleptics
18. Role of olfactory tubercle and nucleus accumbens in the effects of classical and atypical neuroleptics: search for regional specificity
19. A comparison of the abilities of typical neuroleptic agents and of thioridazine, clozapine, sulpiride and metoclopramide to antagonize the hyperactivity induced by dopamine applied intracerebrally to areas of the extrapyramidal and mesolimbic systems
20. Beitrag zur Transmitterhistochemie des Tuberculum olfactorium der Ratte
21. Neurochemical studies with the potential antipsychotic compound trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-di-benz{2,3,:6,7}oxepino[4,5-c]pyrrolidine maleate
22. Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia
23. The treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs
24. The paw test: an animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism
25. The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs
26. The azaphenothiazine prothipendyl is an atypical neuroleptic acting through dopamine D1 and D2 receptors
27. The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats
28. The islands of Calleja complex of rat basal forebrain. III. Histochemical evidence for a striatopallidal system
29. Transneuronal effects of olfactory bulb removal on choline acetyltransferase and glutamic acid decarboxylase activities in the olfactory tubercle
30. Differential projections from locus coeruleus to olfactory bulb and olfactory tubercle
31. Olanzapine: a potential ‘atypical’ antipsychotic agent — phase II clinical findings
32. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations
33. The acute effect of sertindole on brain 5-HT2, D2 and α1 receptors (ex vivo radioreceptor binding sites)
34. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data?
35. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties
36. Biochemical pharmacology of the atypical neuroleptic remoxipride
37. Biochemical profile of risperidone, a new antipsychotic
38. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors
39. Deafferentiation elicits increased dopamine-sensitive adenylate cyclase and receptor binding in the olfactory tubercle
40. Efficacy and safety of sertindole in double-blind, placebo-controlled trials of schizophrenic patients
41. The efficacy and tolerability of sertindole in schizophrenic patients: a pilot, double-blind, placebo-controlled, dose-ranging study
42. Cholinergic systems in the CNS
43. Psychopharmacology of ritanserin: comparison with chlordiazepoxide
44. The importance of serotonin-dopamine interactions in the action of clozapine
45. The behavioral pharmacology of olanzapine, a novel “atypical” antpsychotic agent
46. The pharmacology of olanzapine and other new antipsychotic agents
47. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule
48. Organization of ascending serotonin systems in the adult rat brain
49. Chronic thioridazine treatment differently affects DA receptors in striatum and in mesolimbo-cortical systems
50. Ergometrine induced locomotor activity following intracerebral injection into the nucleus accumbens
51. Further investigations on the effects of ergometrine and other ergot derivatives following injection into the nucleus accumbens of the rat
52. Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity
53. The central olfactory connections
54. Clinical considerations in the use of risperidone
55. Muscarinic receptors of the central nervous system of the rat
56. Serotonin distribution in the limbic system of the rat
57. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound
58. The ascending cholinergic reticular system: neocortical, olfactory and subcortical projections
59. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment
60. On the significance of the increase in homovanillic acid (HVA) caused by antipsychotic drugs in corpus striatum and limbic forebrain
61. Comparative dopamine-cholinergic mechanisms in the olfactory tubercle and the striatum: effects of metoclopramide
62. Pilot clinical study with a new antipsychotic